Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care.
Mediocre balance sheet with moderate growth potential.
Share Price & News
How has Puma Biotechnology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PBYI's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PBYI underperformed the US Biotechs industry which returned 32.4% over the past year.
Return vs Market: PBYI underperformed the US Market which returned 16.4% over the past year.
Price Volatility Vs. Market
How volatile is Puma Biotechnology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
7 hours ago | Simply Wall StIs Puma Biotechnology (NASDAQ:PBYI) Using Too Much Debt?
7 hours ago | Simply Wall StIs Puma Biotechnology (NASDAQ:PBYI) Weighed On By Its Debt Load?
4 weeks ago | Simply Wall StPuma Biotechnology, Inc.'s (NASDAQ:PBYI) Shift From Loss To Profit
Is Puma Biotechnology undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PBYI ($10.53) is trading below our estimate of fair value ($61.33)
Significantly Below Fair Value: PBYI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PBYI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: PBYI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PBYI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PBYI is overvalued based on its PB Ratio (17.8x) compared to the US Biotechs industry average (3.4x).
How is Puma Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PBYI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: PBYI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PBYI's is expected to become profitable in the next 3 years.
Revenue vs Market: PBYI's revenue (8.8% per year) is forecast to grow slower than the US market (9.4% per year).
High Growth Revenue: PBYI's revenue (8.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PBYI's Return on Equity is forecast to be low in 3 years time (0.4%).
How has Puma Biotechnology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PBYI is currently unprofitable.
Growing Profit Margin: PBYI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PBYI is unprofitable, but has reduced losses over the past 5 years at a rate of 22.5% per year.
Accelerating Growth: Unable to compare PBYI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PBYI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.8%).
Return on Equity
High ROE: PBYI has a negative Return on Equity (-177.85%), as it is currently unprofitable.
How is Puma Biotechnology's financial position?
Financial Position Analysis
Short Term Liabilities: PBYI's short term assets ($159.2M) exceed its short term liabilities ($94.5M).
Long Term Liabilities: PBYI's short term assets ($159.2M) exceed its long term liabilities ($145.9M).
Debt to Equity History and Analysis
Debt Level: PBYI's debt to equity ratio (412.7%) is considered high.
Reducing Debt: Insufficient data to determine if PBYI's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PBYI has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PBYI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Puma Biotechnology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PBYI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PBYI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PBYI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PBYI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PBYI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Alan Auerbach (50 yo)
Mr. Alan H. Auerbach is the Founder of Puma Biotechnology, Inc. and has been its Executive Chairman, Chief Executive Officer and President since October 4, 2011 and serves as its Secretary. Mr. Auerbach is ...
CEO Compensation Analysis
Compensation vs Market: Alan's total compensation ($USD3.76M) is above average for companies of similar size in the US market ($USD2.03M).
Compensation vs Earnings: Alan's compensation has been consistent with company performance over the past year.
|CFO & Principal Accounting Officer||1.75yrs||US$665.80k||no data|
|Chief Medical & Scientific Officer||3yrs||US$1.33m||0.070% |
|Senior Vice President of Regulatory Affairs||2.58yrs||US$1.38m||0.022% |
|Senior Director of Investor Relations||8.75yrs||no data||no data|
|Vice President of Human Resources||no data||no data||no data|
|Chief Commercial Officer||0.42yr||no data||no data|
Experienced Management: PBYI's management team is considered experienced (2.8 years average tenure).
|Lead Independent Director||no data||US$357.20k||0.039% |
|Independent Director||2.5yrs||US$327.20k||0.063% |
|Independent Director||6.83yrs||US$342.20k||0.0023% |
|Independent Director||5yrs||US$337.20k||0.039% |
|Independent Director||0.83yr||US$461.94k||no data|
|Director||0.083yr||no data||no data|
|Independent Director||0.75yr||US$834.57k||no data|
Experienced Board: PBYI's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PBYI insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2%.
Puma Biotechnology, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Puma Biotechnology, Inc.
- Ticker: PBYI
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$418.193m
- Shares outstanding: 39.68m
- Website: https://www.pumabiotechnology.com
Number of Employees
- Puma Biotechnology, Inc.
- 10880 Wilshire Boulevard
- Suite 2150
- Los Angeles
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PBYI||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Apr 2012|
|0PB||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Apr 2012|
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatm ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/11 00:45|
|End of Day Share Price||2020/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.